Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,645 stopped studies mapped to Malignant Lung Neoplasm and descendants · 90% state a reason
Over the 1,645 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03148327 | Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized… | Phase 1 / Phase 2 | terminated | May 11, 2017 | Jonsson Comprehensive Cancer Center | Low accrual | Enrollment / accrual |
| NCT03425331 | Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC | Phase 2 | terminated | Feb 7, 2018 | Dana-Farber Cancer Institute | Slow accrual, competing studies, and lack of efficacy | Efficacy / futility |
| NCT04933695 | A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a…(CodeBreaK201) | Phase 2 | terminated | Jun 22, 2021 | Amgen | Futility | Efficacy / futility |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | Phase 1 / Phase 2 | withdrawn | Apr 16, 2020 | Chongqing Precision Biotech Co., Ltd | The sponsor requested to terminate the study. | Other (stated, no rule matched) |
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Apr 14, 2017 | Novartis Pharmaceuticals | Business reasons and not due to any safety concerns | Safety / toxicity |
| NCT06376253 | A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers | Phase 1 | terminated | Apr 19, 2024 | Novartis Pharmaceuticals | Study termination based on sponsor decision due to lack of tolerability observed with… | Sponsor / business decision |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… | Phase 1 | terminated | Sep 5, 2024 | BeOne Medicines | The Sponsor has made the decision to terminate this study due to the lack of promising efficacy,… | Efficacy / futility |
| NCT04585477 | Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) | Phase 2 | suspended | Oct 14, 2020 | Stanford University | pending protocol amendment | Other (stated, no rule matched) |
| NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Phase 1 | terminated | Jun 20, 2024 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Phase 1 | terminated | Oct 7, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns. | Safety / toxicity |
| NCT05967533 | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With… | Phase 1 | suspended | Aug 1, 2023 | University of California, Davis | For internal interim analysis | Efficacy / futility |
| NCT00006344 | Radiation Therapy in Preventing Brain Metastases in Patients With Small Cell Lung Cancer | Phase 3 | withdrawn | May 24, 2004 | Virginia Commonwealth University | PI left institution | Investigator |
| NCT06191250 | --SuPERIOR Trial-- | Phase 2 | terminated | Jan 5, 2024 | University Health Network, Toronto | Study Terminated Prior to trial activation, due to changes in SOC of the treatment | Other (stated, no rule matched) |
| NCT03353428 | Intervention of Engineered Immune Effector T Cells Against Lung Cancer | Phase 1 / Phase 2 | withdrawn | Nov 27, 2017 | Shenzhen Geno-Immune Medical Institute | combine with NCT03356808 | Other (stated, no rule matched) |
| NCT07524257 | Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care… | Phase 3 | withdrawn | Apr 13, 2026 | ImmunityBio, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05130255 | GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 | Phase 1 | terminated | Nov 23, 2021 | Y-mAbs Therapeutics | Decision by Sponsor | Other (stated, no rule matched) |
| NCT03631199 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy…(CANOPY-1) | Phase 3 | terminated | Aug 15, 2018 | Novartis Pharmaceuticals | Results of primary analysis showed addition of canakinumab to combination treatment did not improve… | Safety / toxicity |
| NCT03318939 | Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20… | Phase 2 | terminated | Oct 24, 2017 | Spectrum Pharmaceuticals, Inc | Strategic business decision (unrelated to safety) | Safety / toxicity |
| NCT04984811 | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally… | Phase 2 | terminated | Aug 2, 2021 | NeoImmuneTech | sponsor decision (not for safety) | Safety / toxicity |
| NCT06267001 | A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in…(SKYSCRAPER-15) | Phase 3 | terminated | Feb 20, 2024 | Hoffmann-La Roche | Decision to terminate study was driven by results from preceding tiragolumab study… | Safety / toxicity |
| NCT03637335 | Comparing Palliative Radiotherapy With or Without Carboplatin(METAXIOM) | Phase 3 | terminated | Aug 20, 2018 | Institut Cancerologie de l'Ouest | The study was stopped due to insufficient recruitment. | Enrollment / accrual |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In… | Phase 2 | terminated | Jun 7, 2021 | Regeneron Pharmaceuticals | Sponsor Decision related to study drug supply | Drug supply |
| NCT04748419 | Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting… | Phase 1 / Phase 2 | terminated | Feb 10, 2021 | University of Nebraska | Poor accrual | Enrollment / accrual |
| NCT04189614 | An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With… | Phase 1 | terminated | Dec 6, 2019 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT01451853 | SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss | Phase 2 | withdrawn | Oct 14, 2011 | Sound Pharmaceuticals, Incorporated | Study did not start | Other (stated, no rule matched) |
| NCT02676050 | Visualising c-MET and Activated Neutrophils in Lung Cancer(DUAL) | Early Phase 1 | terminated | Feb 8, 2016 | University of Edinburgh | C-met marker expired | Other (stated, no rule matched) |
| NCT05062980 | Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously…(Acclaim-2) | Phase 1 | terminated | Sep 30, 2021 | Genprex, Inc. | Enrollment was slow, due to competition with the many other clinical trials for the same patient… | Enrollment / accrual |
| NCT06897735 | Exploratory Study of Inhaled Afatinib Dimaleate PK Profile(EDDIS-a1) | Phase 1 | terminated | Mar 27, 2025 | Petrov, Andrey | adjustment of the study design taking into account the receipt of primary data | Other (stated, no rule matched) |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Dec 15, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk… | Other (stated, no rule matched) |
| NCT06558799 | LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With…(LUNAR-4) | Phase 2 | terminated | Aug 19, 2024 | NovoCure GmbH | EF-50/LUNAR-4 was terminated because available real-world data are expected to enable Novocure to… | Safety / toxicity |
| NCT03402880 | ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small… | Phase 2 | withdrawn | Jan 18, 2018 | City of Hope Medical Center | No patients enrolled | Enrollment / accrual |
| NCT06682013 | Virtual Agent Feasibility in Oncology Patients (NTT Data) | N/A | withdrawn | Nov 12, 2024 | Duke University | Poor accrual | Enrollment / accrual |
| NCT03237377 | Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer | Phase 2 | terminated | Aug 2, 2017 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | low accrual | Enrollment / accrual |
| NCT03520686 | Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | Phase 3 | terminated | May 11, 2018 | ImmunityBio, Inc. | There are no longer active subjects on QUILT-2.023. Data will be entered into clinicaltrials.gov… | Other (stated, no rule matched) |
| NCT06685718 | A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor… | Phase 1 | terminated | Nov 12, 2024 | BeOne Medicines | Evaluation on business strategy, not involving safety issue. | Safety / toxicity |
| NCT06704724 | A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other… | Phase 1 | terminated | Nov 26, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT04588246 | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to… | Phase 3 | terminated | Oct 19, 2020 | NRG Oncology | Inadequate accrual rate | Enrollment / accrual |
| NCT03645928 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Phase 2 | terminated | Aug 24, 2018 | Iovance Biotherapeutics, Inc. | After reviewing the available safety and efficacy data to date, Iovance concluded that the study… | Safety / toxicity |
| NCT03337698 | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With…(Morpheus Lung) | Phase 1 / Phase 2 | terminated | Nov 9, 2017 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT04025515 | Molecular Profiling Project | — | suspended | Jul 19, 2019 | National Cancer Centre, Singapore | Discussion under way on how to continue/restart the study in view of slow recruitment rate. | Enrollment / accrual |
| NCT04746924 | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With… | Phase 3 | terminated | Feb 10, 2021 | BeiGene | This decision was conducted by the sponsor based on lack of efficacy and not driven by safety… | Safety / toxicity |
| NCT04878952 | Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve… | N/A | terminated | May 10, 2021 | NRG Oncology | will not be able to meet study accrual objectives. | Enrollment / accrual |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced… | Phase 1 | terminated | Mar 11, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT06653023 | Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer(Wondercel-UWD3) | Early Phase 1 | suspended | Oct 22, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT03684486 | Rehabilitation by Effort for Patients With Advanced Bronchial Cancer(RehabKBP) | N/A | terminated | Sep 25, 2018 | University Hospital, Toulouse | recruitment difficulties | Enrollment / accrual |
| NCT01851395 | Rapid Autopsy and Procurement of Cancer Tissue | — | terminated | May 10, 2013 | National Cancer Institute (NCI) | PI departure. | Other (stated, no rule matched) |
| NCT04786093 | Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC | Phase 2 | terminated | Mar 8, 2021 | University of Texas Southwestern Medical Center | Sponsor decision to halt funding. | Funding |
| NCT05812274 | Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients | N/A | terminated | Apr 13, 2023 | Columbia University | Funding was withdrawn | Funding |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2023 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 16, 2026source: clinicaltrials